Patent · US Active

Anti-PD-L1 antibodies and uses thereof

US10059769B2 · kind B2 · utility

11Cited by

0References

11Claims

0Family size

Assignee

I-MAB · KY

Inventors

Lei Fang · Katy, US
Zhengyi Wang · Shanghai, CN
Bingshi Guo · Shanghai, CN
Jingwu Zang · Shanghai, CN

Key dates

Filing date	Jun 13, 2017
Grant date	Aug 28, 2018
Priority date	—
Expiry date	Jun 13, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.